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ABSTRACT 
We performed a meta-analysis of all published data regarding the possible 
benefits of vitamin D and/or calcium supplementation for increasing bone mineral 
density (BMD) in cancer patients. Currently, there is no medical community 
consensus as to whether vitamin D and/or calcium affects bone health among cancer 
patients enough to offset the effects of chemotherapy. The Department of Defense’s drug 
formulary, managed by the Pharmaceuticals and Therapeutics (P&T) committee, states 
that insurance does not cover multivitamin/multimineral supplements. The lack of 
coverage and consensus leaves patients in the dark about a potential benefit to a treatable 
disease. Therefore, we assessed the known research to offer more clarity to the 
committee. The thesis weighs evidence with a “pooled” effect, or weighted average, 
known as meta-analysis, and assessed risk of bias and quality of evidence via GRADEpro 
software. Of over 700 possible studies, 14 met our inclusion criteria, including four 
randomized control trial (RCT) and 10 observational studies. One RCT (with an outcome 
on 25(OH)D levels) and three observational studies found significant evidence of 
supplementation’s benefits, while the rest showed no significant findings. While 
overall we determined there was no significant benefit, we offer a solid base of 
understanding to the committee and recommend further research. 
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Cancer is a devastating disease and the second most common cause of death in the 
United States after heart disease (Siegel, Miller, & Ahmedin, 2017), and, according to 
Siegel et al., “a major public health problem” (p. 7). In children, the most common 
malignancy among the different types of cancers is leukemia, accounting for about 29% of 
all pediatric cancers (Siegel et al., 2017). Without a cure, medicine has also turned to 
examining the disease’s long-term side effects and treatments (van der Sluis, van den 
Heuvel-Eibrink, Hählen, Krenning, & de Muinck Keizer-Schrama, 2000). These same 
authors noted there are many studies that show cancer patients with reduced bone mineral 
density (BMD) during their therapy treatments. In their study, these authors focused on 
calcium and vitamin D’s effect on BMD (van der Sluis et al., 2000). Many studies consider 
calcium supplementation in combination with vitamin D intake. According to Peterlik, 
Grant, and Cross (2009), both together are generally considered to significantly reduce 
cancer incidence levels. 
The causes of low BMD are not known completely. According to a study by Díaz 
et al. (2008), there have been some general recommendations given to preserve normal 
levels of bone mass, such as physical exercise and the procurement of a balanced nutrition 
to contain adequate proteins, calcium and vitamin D. Additionally, in that same study, it is 
mentioned that sunlight exposure is usually lower for acute lymphoblastic leukemia (ALL) 
children as they accumulate more time indoors or without direct sunlight than healthy 
children do. The lack of sunlight diminishes the absorption of vitamin D, which can affect 
children’s intake and metabolism of this vitamin (Díaz et al., 2008). Another study 
conducted by Simmons et al. (2011), describes some factors that have shown relation to 
low BMD, at least partially, are physical inactivity, prolonged glucocorticoid treatment, 
increased pro-inflammatory cytokines, and vitamin D deficiency/insufficiency.  
Therefore, although we see that some studies do find significant benefits with 
supplementation for cancer patients, unfortunately, others fail to find any significant results 
or fail to measure a valid outcome adequately. The reasons why it is hard to demonstrate 
as significant outcomes vary from study to study. 
xvi 
We perform a meta-analysis to demonstrate whether there is any significance on 
taking vitamin D and/or calcium supplementation to enhance bone mineral density on 
oncology patients. To accomplish this, we have produced a systematic review of published 
studies that are looking for key clinical factors that affect the BMD of these patients. 
Specifically, we evaluated the effect of vitamin D and/or calcium in comparison with 
placebos or standard treatment control groups on bone health outcomes among cancer 
patients by performing a systematic review.  
From the start of the search, it became critical to find a good amount of studies and 
as many as possible. Studies such as randomized controlled trials (RCT) were best but also 
any other non-randomized clinical study meeting this thesis inclusive criterion were 
considered, so a meta-analysis would be viable. This search identified 14 published studies 
for this thesis. Four of these were RCT and the rest were observational studies.  
Observational studies, due to their nature of the lack of randomization, go through 
additional screening to measure their level of bias. This is because observational studies 
are mostly carrying a high risk of bias throughout their phases of development, compared 
to an RCT study, which mostly carries a low risk of bias. This risk of bias assessment is 
analyzed according to a scale commonly used in the medical field. This assessment is called 
the Newcastle-Ottawa scale (NOS) and according to its criteria, each observational study 
receives a scaled metric that helps assess the level of risk of bias according to the criteria 
set by the reviewer. This NOS assessment tool helped determined that, according to our 
criteria, four observational studies were accepted with having a low risk of bias, while the 
rest, six studies were considered to have a medium to high risk of bias. 
A challenge found in most of the studies was that many had their own way of doing 
analysis, and with this came different ways in reporting measurements or a lack of them. 
We considered the most common metrics in use in this thesis. These metrics were 
measurements of the lumbar spine BMD, hip BMD, total BMD, 25(OH)D levels at various 
lengths of time and levels over 40 units at various lengths of time, and last but not least, 
proximal femur BMD. To overcome some of these differences in reporting outcomes, a 
standardized mean difference was used as base comparison for all the continuous unit-
based analyses and odds ratio (OR) used for the dichotomous unit-based analyses. 
xvii 
Additional statistical analysis performed with the studies was to compare their RE, FE, 
heterogeneity, and their probability values for significance between studies if more than 
one study was involved. A significant finding was noted if the 95% confidence interval for 
a SMD for any outcome was entirely above or below zero, suggesting the difference 
between groups was significantly positive or negative.  
Results obtained from this meta-analysis produced statistical evidence that these 
supplements in question are not significant overall for improving BMD. From the RCT 
studies, only one was found to have significant evidence about supplementation making an 
impact on bone health (study by Khan et al.[(2017]), according to its outcome on 25(OH)D 
levels. From the observational studies, just three out of the 10 studies showed some 
significant evidence on the use of supplementation making positive impact: 
• Schnabel et al. (2013), in their hip BMD assessment 
• Schneider et al. (2004) (boys’ group), in their total BMD assessment (see 
Figure 6), and  
• Khan et al. (2010), in their 25(OH)D levels > 40 units at 16 weeks 
assessment (see Figure 7) 
The remainder of the observational studies demonstrated neither positive nor negative 
significant outcomes.  
Many point estimates show increases/benefits for supplementation being effective 
for BMD, but not significantly. Perhaps future studies should be more driven to detect 
smaller differences, perhaps with larger sample sizes.  
As a last step, we looked at evaluating the quality of the evidence with the assistance 
of an analysis software called GRADEpro GDT (GRADEpro GDT, 2015). The 
GRADEpro approach gave us an overview on the certainty of the evidence from the 
outcomes of all of our studies used in this thesis. We used this as a tool to make informed 
decisions regarding how each study is influenced through its certainty and its findings we 
obtained from them. All the RCT studies result in GRADEpro having a certainty of high, 
while all other studies such as the observational studies have some other level of certainty. 
xviii 
Overall, we determined these outcomes with estimates produced by observational studies 
to be rated as very low quality. The exception was for lumbar spine BMD, which we 
estimated as low quality per our GRADEpro quality of evidence assessment. 
These findings add evidence for clinicians and healthcare policy makers for 
decision-making and making recommendations for cancer patients. Our findings should 
also be considered in the context that these supplements are relatively cheap and not 
harmful, but their benefits are also not evidenced. We strongly encourage further research 
to help make conclusions stronger; the results of this thesis hopefully can serve as a basis 
for additional clarity, further analysis, and consideration for the DoD P&T committee. This 
committee controls the formulary that all DoD beneficiaries use. Therefore, this thesis 
offers an effective basis from which the committee can study the effects of vitamin D and 
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Cancer is a devastating disease and is the second most common cause of death in 
the United States after heart disease (Siegel et al., 2017), and considered, according to 
Siegel et al., “a major public health problem” (p. 7). The same authors state that in 2017 
alone, it was projected there would be 1,688,780 new cancer cases in which 10,270 would 
be children (birth to 14 years), and 600,920 cancer deaths (1,190 being children) in the 
United States.  
In children, the most common malignancy among the different types of cancers is 
leukemia, accounting for about 29% of all pediatric cancers (Siegel et al., 2017), with acute 
lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) as the most common 
types (Gurney et al., 2014). Moreover, in another study by Kaste et al. (2006), researchers 
estimate that “[i]n the United States two-thirds of the 3,000-4,000 persons who receive a 
diagnosis of [ALL] each year are children” (Kaste et al., 2006, p. 77).  
In adults, cancer is the second most common cause of death, trailing behind heart 
disease, for all men and women of all ages according to Siegel et al. (2017). According to 
American Cancer Society (2018), 43% of all cancer deaths in men are attributed to cancers 
of the prostate, lung and bronchus, and colon and rectum. For women, 47% of all cancer 
mortality can be attributed to cancers of the breast, lung and bronchus, and colon and 
rectum. Four percent of all cancer deaths are attributed to leukemia among adults 
(American Cancer Society, 2018).  
According to Kadan-Lottick et al. (2001), the stages children with leukemia go 
through have the potential to be a disruptive process for their bone metabolism. The same 
author explains these children are at increased risk for reduced bone peak mass as well as 
for bone fractures. Furthermore, cancer treatment will usually lead patients to have lower 
levels of physical activity, thus further inhibiting bone mineral density (BMD) during and 
after treatment (Kadan-Lottick et al.. 2001). Cancer treatments such as chemotherapy have 
the main benefit such as to augment the survivability of the patients, especially for cancers 
2 
like ALL; however, these treatments tend to induce several negative effects on the body, 
such as alterations in vitamin D absorption. In other words, children’s bone metabolism 
may deteriorate due to mechanisms associated with the treatment or with the illness itself. 
In fact, researchers have found that children after cancer treatment tend to have lower BMD 
when compared to healthy children (Díaz et al., 2008). According to the same author, 
1,25(OH)2 vitamin D or also known as calcitriol, enhances calcium and phosphorous 
absorption through the intestines, as well as assists with bone mineralization. Additionally, 
the same author states that patients with ALL tend to have vitamin D deficits right from 
the beginning of treatment, and sometimes even before treatment, thus representing an 
ideal population to supplement with vitamin D (Díaz et al. , 2008).  
Predictors of childhood cancers continue to be at the forefront of many studies by 
scientists. One of many possible predictors of childhood cancer is environmental exposure, 
perhaps even the parents’ jobs or occupations, although these are mostly speculative. 
Exposure to environmental factors has been evaluated in some studies, such as the potential 
exposures among military personnel who served time in Southeast Asia. Some believe, 
according to Goldberg, Eisen, True, and Henderson (1992), that there were negative effects 
from “a dioxin-contaminated herbicide, also known as ‘Agent Orange’” (Goldberg et al., 
1992, p. 842). Parental occupations is another predictor for childhood cancers as studies 
have looked for evidence suggesting a link, however, according to Savitz & Chen (1990), 
there is not clear evidence of this association. The same authors also describe a parental 
toxicity as a potential mechanism for producing genetic effects that could later alter the 
susceptibility of cancer in the child. Additionally, the authors also state that transplacental 
toxicity could be related to exposures to lead and alcohol though the role of paternal 
occupational exposures is still considered to be more questionable (Savitz & Chen, 1990).  
Moreover, treatment of cancers, especially leukemia, usually goes through 
advanced therapeutic services proven to increase the survival of these individuals with 
ALL. However, among the drawbacks of these treatments is that they enhance the 
susceptibility of certain side effects, which usually worsen, especially after prolonged 
periods of application. Such effects from therapy treatments can be as bad as the “illness 
itself, [the] therapy, poor food intake, poor physical activity, and prolonged rest” (Díaz et 
3 
al., 2008, p. 15). Other factors not mentioned that contribute to deficient BMD after 
treatment are according to Kaste et al. (2006), the “irradiation of endocrine organs that 
control bone accretion …, genetic predisposition …, and pubertal status” (Kaste et al., 
2006, p. 77). Some of these factors, according to the same author, in the long term, “may 
predispose survivors to osteoporosis of greater severity and earlier onset” (Kaste et al., p. 
77). 
According to Simmons et al. (2011), children’s overall cancer survival rate is now 
in excess of 80% (Simmons et al., 2011). Therefore, as stated by van der Sluis, van den 
Heuvel-Eibrink, Hählen, Krenning, & de Muinck Keizer-Schrama, (2000), the emphasis in 
medicine has turned to examining the long-term side effects of the disease and its 
treatments, rather than only focusing on curative agents. Van der Sluis et al. (2000) studied 
the long-term effects in cancer patients by evaluating vitamin D and its effect on BMD 
(van der Sluis et al., 2000). The causes of low BMD are not known completely, however. 
According to Simmons et al. (2011), some factors that have shown relation to low BMD, 
at least partially, are physical inactivity, prolonged glucocorticoid treatment, increased pro-
inflammatory cytokines, and vitamin D deficiency/insufficiency (Simmons et al., 2011). 
Moreover, vitamin D has been found to be insufficient in about 70% children and 
adolescents in the United States (Simmons et al., 2011). Children with leukemia, ALL in 
particular, are suspected to be particularly susceptible to low BMD and this risk may 
“persist into adulthood” (Gurney et al., 2014, p. 2). BMD is usually affected by having this 
pediatric malignancy, but may also by an artifact of receiving high doses of chemotherapy 
treatments in the long-term. According to the same author, these treatments usually include 
high doses of glucocorticoids and methotrexate, both of which interfere with skeletal 
growth and affect BMD recovery. The degree of recovery or decline regarding BMD, 
among cancer survivors of childhood ALL and AML, is not well understood (Gurney et 
al., 2014). 
According to Díaz et al. (2008), there have been some general recommendations 
given to preserve normal levels of bone mass, such as physical exercises, and the 
procurement of a balanced nutrition to contain adequate proteins, calcium and vitamin D. 
The same author says that these recommendations are normally emphasized for children 
4 
with ALL due to their relative attrition on physical activity they are exposed to, at least 
during their treatment periods. Additionally, sunlight exposure is usually lower for ALL 
children as they accumulate more time indoors or without direct sunlight than regular 
healthy children do. The lack of sunlight diminishes the absorption of vitamin D, which 
can affect their intake and metabolism of this vitamin (Díaz et al., 2008). 
Some studies find significant benefits with supplementation for cancer patients; 
unfortunately, some others fail to find any significant results, or fail to measure a valid 
outcome adequately. The reasons why it is hard to demonstrate significant outcomes vary 
from study to study. Some of these reasons include the failure to measure the effect of 
calcitriol in children because of their age when they were in the study. As an example, in a 
study by Diaz et al. (2008) the participants had a mean age of 6.6 years at the end of the 
study. The problem here is that this age is also known as a period of steady bone growth. 
This makes this pubertal period hard to demonstrate measureable or clinically significant 
results for any bone accretion (Díaz et al., 2008). 
Complicating researchers’ ability to properly gauge the effects of supplementation, 
some studies find improved bone health during post-treatment stages. However, other 
factors can confound these relationships, such as how the true amount of any dietary 
supplements taken, and for how long. Another example could be the improvement coming 
naturally from the healthier quality of life after treatment and as the growing stages to 
adulthood of the children in which there are expected stages of bone growth. 
The method for determining which bones to measure BMD among oncology 
patients is based on a whole body of literature regarding cancer and bone health. Lumbar 
spine bone density, for example, has been found to be the primary affected section in both 
men and women that have had various types of cancer. However, other areas are also 
frequently affected and are commonly found by doing a whole body scan. According to 
Guise (2006), screening for BMD has a standard measurement methodology in which they 
usually rely on a special type of equipment known as “dual-energy x-ray absorptiometry 
(DXA)…which has been widely used for quantifying bone loss in the spine, proximal 
femur, and total body” (Guise, 2006, p. 1124). These bone sections will be found with 
measurements in the majority of our included studies. 
5 
In this study, we will perform a systematic review and meta-analysis regarding the 
use of supplementation for oncology patients. Using this methodology, we will look to 
combine multiple studies together that pertain to our research question and weigh all the 
evidence available to make assertions about the relationship. Meta-analyses are commonly 
conducted in scientific fields such as medical scientific research, for example. Meta-
analysis is used with a purpose of pooling or combining findings of multiple studies 
enabling production of a more powerful statistical outcome, or more credible findings 
thanks to the larger amounts of empirical data.  
There have been multiple studies that have made use of meta-analysis techniques 
using military data or involving military or Department of Defense (DoD) populations. For 
example, Wilson’s study (2016) published a meta-analysis evaluating the prevalence of 
military sexual trauma. The author conducted a review of 584 citations of which 69 studies 
were used for the meta-analysis. The main focus was on those studies that contained 
estimates of sexual harassment or sexual assault regarding military service members and 
veterans. Wilson found that the military sexual trauma rates among the women and men in 
their studies were most likely higher than the rates the Veterans Affairs (VA) had suggested 
based on their massive database (Wilson, 2016). 
B. OBJECTIVE 
We are looking to determine whether multiple studies on bone loss in cancer 
patients from taking vitamin D and calcium supplements can be combined to yield evidence 
that such an effect exists.  
C. SCOPE, LIMITATIONS AND ASSUMPTIONS 
All the studies mentioned in this thesis are based on clinical results that are often 
taken many years post-treatment. There is no clear evidence as to whether there is 
substantial benefit for patients with cancer to take these supplements. With no clear 
evidence going forward, health insurance companies such as Tricare for our military would 
probably find it hard to approve vitamin D supplementation for most patients unless it 
actually works. The DoD Defense Health Agency (DHA) manages the medical services 
program known as Tricare. Tricare has expressed support for treatments with vitamin 
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supplementations, but only if there is evidence of their effectiveness and provided by the 
approval of the pharmacy and therapeutics (P&T) committee, per the guidelines set by 
Tyler et al. (2008). This committee manages the drug formulary that is used by Tricare.  
On the other hand, there are some studies that do suggest otherwise, such as a 
randomized controlled trial (RCT) conducted by Khan et al. (2017) in which 84% of 
patients treated with vitamin D3 achieved higher levels of 25(OH)D, compared to only 
10% of the patients receiving the standard treatment group (Khan et al., 2017). 
Additionally, while it may be difficult to find strong evidence of effectiveness of these 
supplements, many doctors say the benefits outweigh the costs for oncology patients 
(Kadan-Lottick et al., 2001). Another key assumption in this thesis is that we are grouping 
studies together with disparate populations and treatments, and cancers. Our methodology 
attempts to address these sources of heterogeneity, however. 
D. COURSE OF STUDY 
The purpose of this thesis is to evaluate if there is any evidence as to whether the 
supplementation of calcium and vitamin D, either together or individually, produce a 
positive effect in BMD or other bone health outcomes. To accomplish this, we have 
produced a systematic review of published studies aforementioned that are looking for key 
clinical factors that affect BMD of oncology patients. Specifically, we evaluate the effect 
of vitamin D and/or calcium in comparison with placebo or standard treatment control 
groups on bone health outcomes among cancer patients by performing a systematic review 




This thesis bases its methodology on the research and analysis protocols of 
Cochrane Handbook of Systematic Reviews of Interventions (Higgins & Green, 2011). We 
detail our data process and our analysis approach in the following sections.  
A. TYPES OF STUDIES, PARTICIPANTS, AND INTERVENTIONS 
We examined both RCTs and non-randomized clinical trial experiments that 
compared the effects of vitamin D or calcium supplementation in cancer patients. Our 
research includes studies, as defined in the handbook by Higgins and Green (2011), as 
RCTs and observational studies that compare clinical effects between patients given 
vitamin D and patients not (or given placebos) (Higgins & Green, 2011).  
We included randomized trials and cluster randomized trials, and included 
observational studies to include case-control, cross-sectional studies, and retrospective and 
prospective cohort studies. We excluded studies that had no comparison arm or studies that 
lacked specificity as it pertains to vitamin D or calcium intake or levels.  
To clearly lay out the specific inclusion criteria we are employing, we use the PICO 
framework (Higgins & Green, 2011): 
• Population: cancer patients 
• Intervention: vitamin D or calcium supplementation 
• Comparison/Comparator: no vitamin D, or calcium (or placebo), or some 
variation of any of these supplements 
• Outcome: bone health outcomes (e.g., bone mineral density) 
After removing duplicate references from the search results, we excluded all studies 
not meeting our inclusion criteria. In addition to screening titles and abstracts, an additional 
researcher, by employing similar screening strategies and applying the inclusion criteria, 
performed the same operations. By independently performing the screening using the 
criteria for study inclusion and working out disagreements, if any, between both 
researchers, we resolved these by discussion. If needed, we allowed for adjudication by a 
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third subject matter expert. Next, we further eliminated studies that failed to meet the 
inclusion criteria upon full-text review. Also considered, were the remaining primary 
studies for further analysis.  
After identifying the studies, we compared the effects of measures between patients 
receiving calcium or and/or those receiving vitamin D supplements to include the 
following: 
• vitamin D alone 
• vitamin D plus calcium 
• calcium alone 
B. TYPES OF OUTCOME MEASURES 
We considered multiple outcomes of interest, with primary outcomes including 
BMD and fracture risk, and as secondary outcomes, any change in vitamin D levels. BMD 
included measures at the hip, lumbar spine, and proximal femur. Vitamin D changes also 
included vitamin D levels or 25(OH)D levels after supplementation. We also considered 
bone specific alkaline phosphatase (BALP) as another outcome of interest. It is important 
to note that studies were not excluded from this review if they did not report an outcome 
of interest. This was done so that there was no bias of the results toward studies selectively 
reporting specific outcomes. However, if a study did not state an outcome of interest, this 
was retained for qualitative and/or descriptive purposes.  
C. SEARCH METHODS USED FOR IDENTIFYING SUITABLE STUDIES 
This thesis employed a thorough search strategy in order to find appropriate and 
applicable studies. Studies based on publication status or type were still considered (i.e., 
had there been any manuscripts found still in press or unpublished, we would have 
considered them) or language. We searched an electronic database, PubMed, in 2018 and 
with no boundaries on publication dates. Also used were some MeSH terms and other 
relevant keywords in the search strategy. The terms used were:  
• musculoskeletal abnormalities 
• infant or child or adolescent or adult 
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• neoplasms 
• vitamin D 
The search performed used an iterative search strategy. For example, upon 
identifying a primary study for inclusion, we did a cross-reference of its references for 
additional references.  
D. DATA EXTRACTION AND MANAGEMENT 
An initial search for studies yielded data on study interventions, and we entered 
these data onto data collection sheets. In addition, we performed this data extraction 
independently and any discrepancies in data extraction were discussed. The extracted data 
had the following guidelines per Anglemyer et al. (2014).  
• Study details: citation, start and end dates, location, eligibility criteria, 
(inclusion and exclusion), study designs compared, interventions 
compared 
• Comparison of supplementation details: effect estimates from each study 
design within each publication 
• Risk of bias details: all elements needed to determine the risk of bias 
within each primary study 
• Outcome details: primary outcomes identified in each study. (Anglemyer 
et al., 2014, p. 6) 
E. ASSESSMENT OF RISK OF BIAS IN INCLUDED STUDIES 
Once more, following methodology outlined in Higgins (2011) cited by 
Anglemyer, Agrawal, & Rutherford, (2014), this thesis “independently assessed risk of 
bias for each study using the bias assessment tool described in the Cochrane Handbook” 
(emphasis added) (Anglemyer et al., 2014, p. 6). An additional researcher independently 
assessed these assessments, as well, and if there were any disagreement in assessment, we 
discussed differences and used a third researcher to break the tie. Higgins and Green (2011) 
describe a methodology for assessing the risk of bias that we used for our review. This 
methodology uses six domains for study evaluation: “sequence generation, allocation 
concealment, blinding, incomplete outcome data,… selective outcome reporting [and other 
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potential biases]” (Higgins & Green, 2011, p. 8.44). The details of the bias assessment 
analysis are detailed in the following list as cited by Anglemyer et al. (2014): 
• Sequence generation (checking for selection bias) 
• Adequate: investigators described a random component in the sequence 
generation process, such as the use of random number table, coin tossing, 
card or envelope shuffling  
• Inadequate: investigators described a non-random component in the 
sequence generation process, such as the use of odd or even date of birth, 
algorithm based on the day or date of birth, hospital or clinic record 
number 
• Unclear: insufficient information to permit judgment of the sequence 
generation process 
• Allocation concealment (checking for selection bias) 
• Adequate: participants and the investigators enrolling participants cannot 
foresee assignment (e.g., central allocation; [sic] or sequentially 
numbered, opaque, sealed envelopes) 
• Inadequate: participants and investigators enrolling participants can 
foresee upcoming assignment (e.g., an open random allocation schedule, a 
list of random numbers), or envelopes were unsealed, non- opaque or not 
sequentially numbered 
• Unclear: insufficient information to permit judgment of the allocation 
concealment or the method not described. 
• Blinding (checking for performance bias and detection bias) 
• Adequate: blinding of the participants, key study personnel and outcome 
assessor and unlikely that the blinding could have been broken. Not 
blinding in the situation where non-blinding is unlikely to introduce bias 
• Inadequate: no blinding or incomplete blinding when the outcome is likely 
to be influenced by lack of blinding 
• Unclear: insufficient information to permit judgment of adequacy or 
otherwise of the blinding 
• Incomplete outcome data (checking for possible attrition bias through 
withdrawals, dropouts, protocol deviations) 
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• Adequate: no missing outcome data, reasons for missing outcome data 
unlikely to be related to true outcome or missing outcome data balanced in 
number across groups 
• Inadequate: reason for missing outcome data likely to be related to true 
outcome, with either imbalance in number across groups or reasons for 
missing data 
• Unclear: insufficient reporting of attrition or exclusions  
• Selective reporting 
• Adequate: a protocol is available which clearly states the primary outcome 
is the same as in the final trial report 
• Inadequate: the primary outcome differs between the protocol and final 
trial report 
• Unclear: no trial protocol is available or there is insufficient reporting to 
determine if selective reporting is present 
• Other forms of bias 
• Adequate: there is no evidence of bias from other sources 
• Inadequate: there is potential bias present from other sources (e.g., early 
stopping of trial, fraudulent activity, extreme baseline imbalance or bias 
related to specific study design) 
• Unclear: insufficient information to permit judgment of adequacy or 
otherwise of other forms of bias. (Anglemyer et al., 2014, p. 6) 
As an additional evaluation tool for the measurement of bias in observational 
studies, a method is commonly used in the medical field named the Newcastle-Ottawa 
Scale (NOS). This method by Wells et al. (2008) defines a quantitative assessment scale 
that enables us to assess each observational study according to three broad areas: selection, 
comparability, and exposure (Wells et al., 2008). This method is useful for this review as 
it evaluates the quality of observational studies and can act as a stratification tool for 
subgroup analysis. See the reference for Wells for details on the Newcastle-Ottawa Scale 
assessment tool. 
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F. STATISTICAL METHODS  
In general, we retained the raw data extracted from the primary studies. However, 
if a study provided summary outcome measures including risk ratio (RR), odds ratio (OR), 
or hazard ratio (HR), we also extracted those results.  
1. Data Synthesis 
We synthesized data using meta-analytical procedures, when appropriate. 
Specifically, we pooled studies that had similar design (e.g., observational studies vice 
RCTs) and similar comparison arms (e.g., vitamin D supplementation versus placebo). We 
analyzed the pooled data using both a fixed-effect (FE) and a random-effects (RE) model. 
We used the Dersimonian and Laird method for the random-effects model (Dersimonian 
& Laird, 1986). The majority of the included studies were analyzed with a random-effect 
model, because, as expected, we found considerable heterogeneity between studies. Had 
we used a fixed-effect model, we would have assumed that the studies had a common 
estimator common between them, thus enabling a common true effect size for our analysis 
across their populations.  
When pooling our data initially, we found that the data in various publications were 
reported in dissimilar units. For this reason, and to be able to compare many outcomes 
together so what we can perform pooled estimates, we use the standardized mean 
difference (SMD). The SMD allows for the researcher to pool outcomes that come from 
studies using different measurement scales. The SMD combines these different outcomes 
to a more uniform scale that can facilitate the assessment of relative intervention and 
variability between those observed studies. Further, the SMD equals the “difference in 
mean outcome between groups [directly proportional to the] standard deviation of outcome 
among participants” (Higgins & Green, 2011, p. 256). Specifically, Hedges and Olkin 
(1985), describe an effect size measurement called Hedges’ (adjusted) g, which has the 
purpose of differentiating one group from another. They derive this method as: 







where the numerator is the difference in the means and the denominator has the standard 
deviation that is either weighted (as used by Hedges and Olkin) or pooled (used by other 
authors) (Hedges & Olkin, 1985).  
Additionally, when pooling the data, we needed to account for individual study 
sizes and their variability. Therefore, whether using a RE or a FE model, we employed a 
weighted average for each study. In the end, the sum of all weights across all studies in a 
meta-analysis should sum 100%. In FE models, all studies in a meta-analysis share 
common estimator (a common true effect size). This model assumes that all factors 
affecting the effect are the same across all populations studied. Additionally, the FE 
assumes that random error explains the difference between studies. The RE model assumes 
the studies are drawn from populations that are different (in turn, affecting effect 
estimates). It assumes that random error and true variation explains the difference between 
studies. Another assumption of RE is that k number of studies included in the meta-analysis 
are a random selection from a larger population of studies. Lastly, the RE model assumes 
that the true effects or outcomes in the population of studies are normally distributed ( 2τ  
is the variance of true effect in population [the amount of heterogeneity in true effects]). 
The FE model is fitted with weight as determined by 1i
i
w ν= , while the RE model 








, where 2τ  denotes the variance of the true-effects or 
outcomes in the population (or also interpreted as the amount of heterogeneity in true-
effects). The iν  denote the variance for study i. In cases where discrepancies were noted 
between the FE and RE models, we performed a search for possible causes, including 
performing subgroup analyses.  
To perform an assessment in the value of the review’s findings, we also employed 
a quality assessment tool called GRADEpro (GRADEpro GDT, 2015). With this software 
tool, GRADEpro, an evidence table and summary of findings were produced (GRADEpro 
GDT). Some additional benefits of using this software tool is that it can be used as an aid 
for healthcare leaders to have concise and important information that can be useful for 
different purposes, such as for analyzing different healthcare choices, and for policy 
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evaluations, among other things. These assessments can be found in Appendix B. All 
statistical analyses were performed in R using packages including meta (Schwarzer, 2007) 
and metafor (Viechtbauer, 2017) and RevMan (2014).  
2. Assessment of Heterogeneity 
We combined data from selected studies to compare vitamin D or calcium 
supplementation effects on bone outcomes in cancer participants. We pooled data from the 
RCTs and observational studies separately. Because of various dosings, supplementations, 
cancer diagnoses, and even patient settings, we had an expectation of obtaining high 
heterogeneity between primary studies. To determine the extent of heterogeneity between 
studies, we used the I2 statistic and the X2 statistic with a significance level of 0.05. Further, 
we qualitatively assessed heterogeneity using the I2 statistic as follows: between 30% and 
60% is moderate heterogeneity, 50% to 90% substantial heterogeneity, and 75% to 100% 
as a high level of heterogeneity.  
3. Subgroup Analysis and Investigation of Heterogeneity 
We also explored heterogeneity by performing analysis on subgroups. The goal 
here was to analyze the effects of the supplementation, but also to have the effects be 
stratified by stratum-specific heterogeneity groups. We also aimed to examine comparisons 
of pooled outcomes between pediatric and adult subgroups.  
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III. STUDIES 
The electronic search yielded 729 studies of which their abstracts were initially 
pulled. After sorting out a few duplicates (n = 12), we excluded a large number of studies 
based on their abstract clearly not meeting our inclusion criteria (n = 677). We pulled the 
remaining 40 studies for full text review to determine if they met our inclusion criteria. We 
identified a total of 11 studies with an additional three studies found from cross-referencing 
bibliographies of included studies, yielding 14 total primary studies. Four RCT and 10 
observational studies met our inclusion criteria. A flow diagram (see Figure 1), adapted 
from Moher et al., (2009), illustrates the selection process. 
 
Figure 1. Study flow diagram. Adapted from Moher et al. (2009) 
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A. INCLUDED STUDIES 
The following details the studies we included. These 14 studies were published 
between 1989 and 2017 and met our inclusion criteria. 
Demirsoy et al. (2017) performed a study to find how the supplementation of 
vitamin D and calcium can be related to children with ALL. They started their study in 
March 2013 and lasted 20 months at the Pediatric Hematology Unit in the Kocaeli 
University. They had 93 participants and their ages ranged from one to 18 years of age at 
their time of diagnosis. There were 22 siblings nearest to some of these patients enrolled 
in the trial as well. Three patients dropped due to resistance, induction failure, and stem 
cell transplantation. Study observed that calcium and Vitamin D supplementation in these 
patients was not significant to halt the loss in bone mineral density during the intensive 
chemotherapy, however, as other studies show, as there is a gradual decrease in the first 
two years, there is also a gradual increase afterward. 
Díaz et al. (2008) investigated in a randomized case-control trial, how effective the 
supplementation of calcitriol could protect the bone mass of 16 pediatric participants in a 
study during a period of 12 months. They made two equal groups split randomly and only 
one group was to receive the supplementation. These children participated starting in June 
2001 for 21 months and they did this after being in remission of chemotherapy for a month. 
Group One received calcium and calcitriol and Group Two received only calcium. In this 
other study, they found that calcitriol was well tolerated and that it enhanced lumbar bone 
growth in participants that initially had reduced lumbar bone mineral density. 
Iniesta et al. (2016) investigated 25(OH)D plasma concentrations and factors that 
contributed to inadequate vitamin D levels within the study participants. 82 consecutive 
patients and 35 healthy controls were recruited who were part of the prospective cohort of 
Scottish children treated for cancer. The study began in August 2010 and ended 41 months 
later at Edinburgh, or Ninewells Hospital in Dundee. Measurements obtained at baseline 
and at 3, 6, 9, and 12 months, and every 6 months thereafter. The results of this study were 
similar with pediatric oncology participants with matched age of healthy control group on 
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the inadequacy of 25(OH)D. However, the pediatric cancer patient cohort showed no 
seasonal variations. 
Jain et al. (2017) did a cross-sectional observational study of childhood ALL 
survivors, diagnosed and treated between 1996 and 2008, and who have been in therapy 
cessation for at least 2 years. A total of 65 pediatric ALL survivors and 50 siblings enrolled 
for evaluation. These participants did the study in India. Their bone mineral density was 
evaluated and then transformed into z-scores. Findings showed these score values were not 
that different among participants and siblings. Therefore, as Jain et al. (2017) concluded, 
“there was no significant adverse impact of the disease or its treatment, including cranial 
irradiation on BMD in ALL survivors” (Jain et al., 2017, p. 6). 
Kaste et al. (2014) performed a RCT for 275 participants having a median age of 
17 years. These participants were survivors from having leukemia during treatments 
ranging in the years of 1984 to 1997, and they have been cleared for five years or more. 
Blinded to supplementation, the treatment group received daily calcium and 
cholecalciferol. Similar looking supplement tablets filled with inactive ingredients were 
given to the placebo group. This is the second RCT study so far after Diaz et al., however, 
in this one it was found that neither the nutritional counseling nor the supplementation 
given for two years were significant at increasing their bone mineral density. 
Khan et al. (2010) in this prospective study they performed an effects analysis on 
how vitamin D levels affect 25(OH)D serum levels as well as how it affects for pain in the 
joints and for fatigue in women that start the treatment with letrozole for breast cancer. 
Women were given 50000 IU weekly of oral vitamin D3 for a 16 week time with weekly 
follow-ups. However, this high dose was only given to women that had low levels of 
25(OH)D in their serum that was less than or equal to 40 ng/ml which accounted for a total 
of 47 women, while 13 women had higher levels so these were given standard dosage. 
Going back to observational studies, the results of this study showed a significant 
improvement between other things, on joint pain experienced by women that were starting 
treatments with letrozole. 
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Khan et al. (2017) conducted a randomized trial of vitamin D in 160 women with 
breast cancer that were being treated with letrozole. Medication or supplementation of 
vitamin D3 was randomized with a placebo-controlled trial to analyze if vitamin D3 
supplementation given weekly for 24 weeks can prevent worsening symptoms of their 
musculoskeletal system. Participants were asked to enroll if they had stage I-III hormone 
receptor positive breast cancer and which were about to start a letrozole treatment as well 
as having a low level of 25(OH)D less than or equal to 40 ng.ml. This study is the third 
RCT so far and it concluded that the intake of vitamin D3 at 30000 IU per week dose was 
found to be safe for women that were starting the abovementioned treatment. Their serum 
levels of 25(OH)D increased as their results showed. 
Leonova et al. (2015) did a cross-sectional study to look at the effects of vitamin 
D3 and calcium supplementation along with TSH therapy on bone mineral density. A total 
of 124 participants were invited to the study as a follow up for possible radiation exposure 
after a 14-year timeframe since the Chernobyl accident. Conclusions for this study showed 
beneficial effects on bone mineral density from the intake of vitamin D3 and calcium as 
well as evidence that there is no effect on bone mineral density from having TSH-
suppressive therapy treatment. 
Modan-Moses et al. (2012) performed a study to assess vitamin D levels in 
children with cancer and to try to find reasons to explain any deficiency. A total of 142 
patients gave blood specimen to get these measurements and were taken between July 2010 
and February 2011. The study took place in Israel. Participants with initial low 25(OH)D 
levels were offered supplementation. Patients were also offered glucocorticoids if needed 
as well as calcium intake, besides the maintenance, if any, given of 25(OH)D. This study 
showed they were unable to obtain a healthy control group, however it was not considered 
critical as they considered the medical history of all of their patients as a sort of baseline. 
Results showed that 24.6% of participants were vitamin D deficient, while 23.2% were 
insufficient. Additionally, participants that had a history of a malignant disease were high 
in both of the vitamin D problems. 
Peppone et al. (2011) performed a retrospective study that analyzed women 
diagnosed with stage 0-III breast cancer to study various effects of vitamin D 
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supplementation to include bone mineral densities. All 224 women in the study were 
prescribed supplementation of vitamin D, either a low dose or a high dose depending on 
baseline total of 25(OH)D levels. These doses were administered once weekly. In the 
results, only 126 women completed the follow up and those that had 25(OH)D levels <32 
ng/ml had significantly lower mean BMD than those with levels over 32 ng/ml. 
Rai et al. (2008) performed a RCT in two phases. Study one involved estimating 
the prevalence of diminished bone mineral density in children with leukemia. Study two is 
the RCT phase. Participants were at St. Jude Children’s Research Hospital. Phase one had 
424 participants 279 of which were selected due to their BMD deficit to participate in the 
second phase as the RCT study. Participants for study two had continuous clinical nutrition 
services occurring at three-month intervals for a two-year study intervention. The placebo 
tablets were also masked of texture and flavor to aid in concealment by the research staff. 
Outcome from this RCT study, which is the fourth and final RCT of our thesis, describes 
among other things, that BMD is deficit among most participants, with only 34% of the 
study cohort falling at the mean or greater. 
Schnabel et al. (2013) performed a retrospective clinical study that analyzed 36 
subjects composed of 13 males and 23 females of which their ages ranged from 32–63 
years. Ten of these participants did not complete the treatment, as it is not specified in the 
study. In addition, one other male participant mentioned as well, is unknown of his status 
throughout the study. This brought the analysis down to 25 complete results. The work in 
this study was to analyze the effects of vitamin D3 on mineral bone density in patients that 
have NF1. Study results for this study describe that the treatment with cholecalciferol 
proves to be effective for increasing bone mineral density in adults having NF1. 
Schneider et al. (2004) performed an observational study analysis involving 208 
children that underwent total thyroidectomy due to thyroid carcinoma. Of this 208, 119 
were girls. These patients were referred to the study authors’ institution for radioiodine 
treatment after having their thyroidectomy treatment due to their thyroid carcinoma 
disease. Intervention divided them into two groups, one placebo and one receiving AT-10/
CA supplementation. In this study from Schneider et al., final observations showed 
measureable disturbances in the growth-related rate of bone mass accrual. This was seen 
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only in the boys and the effects from this were neutralized apparently by the 
supplementation they received. 
Watsky et al. (2014) conducted a sub study from a RCT to investigate how 
supplementation of vitamin D and/or calcium affects bone mineral density in children with 
leukemia. A total of 424 patients from ages 9 to 36 years of age when enrolled completed 
the study. All patients were treated at a single institution between 1984 and 1997. Their 
treatment consisted of blood serum samples obtained at baseline visit beside other 
information obtained from medical charts, and their nutritional intakes from validated 
questionnaires that were used to estimate the supplementation intakes. Their findings from 
this study, contrary to the previous from Schneider et al. (2004) where there was at least 
some partial positive disturbance from supplementation, this one showed the 
supplementation intake did not have a relation to bone outcome in these children who 
survived leukemia.  
B. EXCLUDED STUDIES 
We excluded 29 studies following full-text review for various reasons. The 
exclusions were mainly because the study lacked the comparison of a treatment and a 
placebo group (n = 29). In addition, some of these studies studied only the benefits and 
nutritional behavior outcomes of vitamin D (n = 6) with no comparison. Others did not 
involve cancer patients (n = 10). For detailed descriptions of these excluded studies, see 
Appendix A.  
C. BIAS ASSESSMENTS 
We appraised the studies and evaluated whether their explanations or definitions of 
various common sources of bias were satisfactory. Four RCTs, Diaz et al. (2008), Kaste et 
al. (2014), Khan et al. (2017), and Rai et al. (2008), were generally found to be free of 
obvious bias though Diaz, Khan, and Kaste had an unclear risk of selective reporting bias. 
See Figures 2 and 3. We also rated observational studies using this same scale, as per the 
Cochrane guidelines (Higgins & Green, 2011) even though by design they will be high risk 
using these risk of bias criteria.   
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Figure 2. Risk of bias summary: The authors’ judgments for all risk of 
bias items for each of our 14 studies. Adapted from 
Higgins and Green (2011). 
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The rating process essentially allows the researcher to assign one of three choices: 
“yes,” “no,” or “unclear” to each criterion. Also with choices, the overall risk of bias has 
“low,” “unclear,” or “high” because of these assessments. In Figure 3, we see that 45% of 
studies had either low risk or unclear risk due to participant selection. Additionally, 45% 
of studies also had either a low risk or unclear risk for blind control of patients as a degree 
of performance. In addition, about 45% of studies had either a low risk or an unclear risk 
of bias for blinding of outcome assessment as a detection measure. About 75% of studies 
had either a low or an unclear risk due to attrition. Of the RCTs, all were found to be the 
lowest in risk mainly due to their design employing randomization. However, only three 
of the four RCTs were found to have their measure of risk of bias to be low for their 
selection protocol (Kaste et al., 2014; Khan et al., 2017; Rai et al., 2008), while one had an 
unclear risk (Díaz et al., 2008). Figure 3 is adapted from the RevMan study analysis 
software made by the Cochrane Collaboration (Higgins and Green 2011). 
 
Figure 3. Risk of bias summary: displays pooled studies and how the overall 
risk of bias affects each control. Adapted from Higgins and 
Green (2011). 
As part of our planned analyses exploring the source of heterogeneity between 
studies, we performed subgroup analyses by risk of bias groups. For our identified non-
randomized studies, we consider the following as criteria for risk of bias subgroups: 
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• High or medium risk of bias = 7 or fewer stars 
• Low risk of bias = 8 or 9 stars 
Using these criteria, Schnabel et al. (2013), Iniesta(a) et al. (2016), Khan et al. 
(2010), Peppone et al. (2011), Schneider et al. (2004), and Watsky et al. (2014) all had a 
high/medium risk of bias. For a good example of why we concluded high or medium risk 
of bias for these studies, we can point to the cohort study by Watsky et al. Using the NOS 
scale, we note that the study had two stars in the selection category as it failed to show the 
use of a comparison control group as well as the demonstration of the outcome not being 
present prior to the start. For the comparability category, we assigned the maximum of two 
stars for controlling two different outcomes of interest. However, in the last category of 
outcome assessment, the study authors made no statement adequate to explain the loss to 
follow-up of participants. The rest of the studies, Demirsoy et al. (2017), Leonova et al. 
(2015), Modan-Moses et al. (2012), and Jain et al. (2017), had low risk of bias, as seen in 
Table 1 (adapted from Anglemyer, Horvath, & Rutherford 2014). We partitioned the 
studies with lower risk (or highest amount of stars) and those studies that had a higher risk 
(or fewest amount of stars).  
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Table 1. Evaluation summary of included studies via the use of the 
NOS assessment for observational studies. Adapted from 
Anglemyer et al. (2014) 
 
 
Please see the Newcastle-Ottawa scale reference by Wells et al. (2008) for 
information summarizing the risk of bias assessments for the observational studies. 
Stars, n
Comparability‡ Exposure§
Demirsoy 2017 4 2 3
Iniesta (a) 2016 2 1 3
Khan 2010 2 1 3
Leonova 2015 3 2 3
Modan-Moses 2012 3 2 3
Peppone 2011 3 1 2
Schnabel 2013 2 1 2
Schneider 2004 2 1 3
Watsky 2014 2 2 2
Jain 2017 4 1 3
Selection†
§ Maximum 3 stars
Cohort studies
Study, Year (Reference)
† Maximum 4 stars
‡ Maximum 2 stars
Case Control studies
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IV. META-ANALYSIS RESULTS AND GRADEpro QUALITY OF 
EVIDENCE 
In this chapter, we provide results for each outcome using evidence from both 
randomized and observational studies. First, we look at all RCT studies, followed by the 
observational studies, and lastly some additional subgroup analyses that could include both 
of these types of designs.  
A. BONE MINERAL DENSITY 
The studies in this thesis that contained a quantitative assessment of BMD are 
described in this section. There was significant evidence in BMD differences related to the 
intake of supplementation of vitamin D3 and calcium in certain studies. However, we only 
made a note of this evidence in singular studies and not as a pooled effect. Jain (2017) 
noted studies that found differences included a subgroup of boy cancer patients in 
Schneider (2004) and Schnabel (2013), but also a slight positive difference for the study in 
both of its subgroups. Overall, there was no significant evidence evaluating the pooled 
effects from BMD outcomes. There were also some single studies slightly negative effects 
of supplementation such as the subgroup of girl cancer patients in Schneider (2004), Diaz 
(2008), and Kaste (2014), though none were significant. More details can be found in the 
following subsections. 
1. Lumbar Spine BMD 
This section contains the studies that evaluated whether supplementation affected 
BMD measured specifically at the lumbar spine. This is one of the most common 
approaches to measuring BMD and was the most commonly reported outcome from all the 
studies. 
a. Number of Studies that Estimated This Outcome 
We pooled together five studies, two RCT and three observational, which 
performed lumbar spine BMD measurements to evaluate the pooled effect. The two RCT 
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were Diaz et al. (2008) and Kaste et al. (2014), and the three observational studies included 
Jain et al. (2008), Leonova et al. (2015), and Schnabel et al. (2013).  
b. Studies that Found a Positive or Negative Effect 
Neither of the RCTs found a significant effect of calcium and vitamin D 
supplementation for improving BMD in the lumbar spine. In fact, both studies have 
negative point estimates, suggesting a slight decrease overall, though these results are 
highly variable. We derived four point-estimates from three observational studies. One 
study (Jain 2008) had two different exposure groups compared to a placebo and both were 
included in our analysis. Of the four point-estimates from observational studies, three 
showed an improvement in lumbar spine BMD. However, none was significant. 
c. Pooled Effects 
The pooled effect of supplementation from the two RCTs (see Figure 4) shows no 
significant effect of supplementation on lumbar BMD (SMD=-0.06; 95% CI= -0.29, 0.17). 
In all, there were 149 participants who received supplementation and 142 participants from 
a control group. The RE p-value was not significant (p=0.59), and the test for heterogeneity 
indicated no evidence (p=0.57).  
 
Figure 4. Lumbar spine BMD measurements analysis from RCT studies. 
Adapted from Higgins and Green (2011). 
Further, we pooled the four point-estimates from the observational studies (see 
Figure 5) and found no significant effect from supplementation on lumbar BMD 
(SMD=0.15; 95% CI -0.09, 0.38) from the RE model. In total, 132 participants received 
supplementation, and 155 participants made up the control treatment group. The 
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heterogeneity test between the groups was not significant, indicating no important 
differences between studies and that a FE model may be an appropriate assumption.  
 
Footnotes: (in order of appearance) Jain 2017(1): calcium vs. low calcium supplements 
comparison. Jain 2017(2): vitD vs. low vitD supplements comparison.  
Figure 5. Lumbar spine BMD measurements analysis from observational 
studies. Adapted from Higgins and Green (2011). 
2. Total BMD 
a. Number of Studies that Estimated This Outcome 
Only one RCT (Diaz 2008) and two observational studies (Jain [2017], and 
Schneider [2004] with two sub studies) evaluated the effects of supplementation on total 
BMD.  
b. Studies that Found a Positive or Negative Effect 
In the RCT, there was a non-significant negative effect of calcium and vitamin D 
supplementation for improving total BMD (SMD=-0.89; 95% CI -2.01, 0.24). In the 
observational studies, the overall effect for RE provided no significant results, however, 
FE did provide significant results, and their heterogeneity was significant at 94%. Neither 
of the two point-estimates obtained from Jain et al. (2017) were significant. We note that 
Schneider et al. (2004) found that the point estimate for the boys’ group was highly 
significant with a p-value of less than 0.01, while the same effect was less significant 
among the girls with a p-value of 0.09.  
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c. Pooled Effects 
We did not pool effects from RCTs because we only had one RCT that evaluated 
total BMD. The RCT included only five participants with supplementation and six 
participants from a control group. The pooled effect from the two point-estimates from Jain 
et al. (2017), though positive, remained non-significant. Together with the results from Jain 
et al., we note that Schneider et al. (2004) also stratified their results by gender. We found 
that, if we assumed a FE model, the pooled effects would actually be significant, indicating 
a positive effect of supplementation on total BMD (SMD=0.39; 95% CI 0.15, 0.62), 
however the RE model may be more appropriate in the presence of high heterogeneity. 
One of the four estimates found a significant positive effect of calcium and vitamin D 
supplementation for improving total BMD (SMD=2.08; 95% CI 1.55-2.62), which was 
specifically among boys (Schneider et al.). However, an opposite effect was found among 
girls (SMD=-0.33; 95% CI -0.71, 0.05) (Schneider et al.). The authors note that these 
differences may be due to basically their gender-related differences such as in muscle bone 
proportions and the estrogen-induced enhancement responding differently within their 
bone cells due to this induced stimulation (Schneider et al., 2004). The total number of 
participants who received supplementation was 147 and they were compared to 175 who 
were in the control group. Heterogeneity between the four studies was significant (p=0.01) 
and substantial heterogeneity was noted (I² = 94%) (See Figure 6).  
 
Footnotes: (in order of appearance) Jain 2017(1): calcium vs. low calcium supplements 
comparison. Jain 2017(2): vitD vs. low vitD supplements comparison. Schneider 2004(1): boys. 
Schneider 2004(2): girls. 
Figure 6. Total BMD measurement analysis from observational studies. 
Adapted from Higgins and Green (2011). 
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3. Hip BMD 
a. Number of Studies that Estimated This Outcome 
Only two studies evaluated BMD measured at the hip, one RCT (Diaz 2008) and 
one observational study (Schnabel 2013).  
b. Studies that Found a Positive or Negative Effect 
In the one RCT, there was a non-significant reduction in hip BMD among the 
supplemented group in comparison to the control group (SMD=-0.91; 95% CI -2.19, 0.36).  
In the one observational study, there was a significant positive effect of calcium and 
vitamin D supplementation for improving BMD in the hip (SMD=1.17; 95% CI 0.38, 1.96).  
c. Pooled Effects 
We did not pool the data for this outcome because we only had single studies. The 
findings from the RCT came from a study of five participants with supplementation and 
six participants from a control treatment group. The observational study evaluated a total 
of 25 participants with supplementation and 10 participants from a control group.  
4. Proximal Femur BMD 
a. Number of Studies that Estimated This Outcome 
Only one observational study (Leonova 2015) performed proximal femur BMD 
measurements.  
b. Studies that Found a Positive or Negative Effect 
In this single study, there was no effect of calcium and vitamin D supplementation 
for improving BMD in the proximal femur (SMD=0.00; 95% CI -0.37, 0.37).  
c. Pooled Effects  
In the one study, a total of 45 participants received supplementation and 79 
participants were in the control treatment group.  
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B. 25(OH)D LEVELS  
This section contains all the study analyses that pertain to the measurement results 
of vitamin D levels provided the results and a baseline were given in each study. Since 
vitamin D is critically important for the proper development of mineral bone density, a 
study would be significant if it shows evidence of this relationship with supplementation. 
Single study effects that demonstrate positive evidence of given supplementation are from 
Khan (2017), and studies with a slight positive effect are from Demirsoy (2017) and 
Peppone (2011) for both of its subgroups. Studies with a slight effect towards controls are 
from Modan-Moses (2012), and Iniesta(a) (2016). The meta-analysis had one study with 
significant findings towards supplementation and another study slightly towards control, 
which gave an overall non-significant finding regarding supplementation effects. More 
details on these studies are found in the following subsections. 
1. At Four Weeks 
The 25(OH)D levels at four weeks measurements taken from studies that provided 
this information is described here. 
a. Number of Studies that Estimated This Outcome 
Only one study (Demirsoy 2017) evaluated 25(OH)D levels at four weeks 
measurements after supplementation. .  
b. Studies that Found a Positive or Negative Effect 
In this single study, there was a slight positive effect of supplementation for 
improving 25(OH)D levels at four weeks, though this was not significant (SMD=0.05; 95% 
CI -0.5, 0.59).  
c. Pooled Effects 
We did not pool these effects because we identified only one study. The study 
included a total of 34 participants with supplementation and 21 participants from a control 
treatment group.  
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2. At 12 Weeks 
The 25(OH)D levels at 12 weeks measurements taken from studies that provided 
this information is described here. 
a. Number of Studies that Estimated This Outcome 
Only one RCT (Khan 2017) and one observational study (Modan-Moses 2012) performed 
25(OH)D levels at 12 weeks measurements. 
b. Studies that Found a Positive or Negative Effect 
In the RCT, there was significant, positive effect of vitamin D supplementation for 
improving 25(OH)D levels at 12 weeks (SMD=1.96; 95% CI 1.57, 2.36). However, in the 
observational study, there was no similar effect (SMD=-0.05; 95% CI -0.64, 0.54).  
c. Pooled Effects 
Due to different designs, we did not pool the two studies together. The RCT 
evaluated 70 participants with supplementation and 77 participants in the control group. 
The observational study included very few participants, 12 with supplementation and 130 
in the control group.  
3. At 16 Weeks 
The 25(OH)D levels at 16 weeks measurements taken from studies that provided 
this information is described here. 
a. Number of Studies that Estimated This Outcome 
Only one observational study (Peppone 2011) was identified that evaluated 
25(OH)D levels at 16 weeks. The authors had two exposure groups: low dose and high 
dose supplementation.  
b. Studies that Found a Positive or Negative Effect 
Both the low dose and the high dose supplementation groups showed a slight 
improvement in 25(OH)D levels at 16 weeks, though neither was significant.  
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c. Pooled Effects 
The pooled effects from Peppone 2011 indicated no significant effect of 
supplementation (low dose or high dose) on 25(OH)D levels at 16 weeks (SMD=0.31; 95% 
CI -0.19, 0.81). The authors included 64 participants with high dose supplementation, 53 
participants with low dose, and 9 participants from a control group. The test for 
heterogeneity was no significant (p=0.93).  
4. Greater than 40 Units at 10 Weeks 
The 25(OH)D levels greater than 40 units at 10 weeks measurements taken from 
studies that provided this information are described here. 
a. Number of Studies that Estimated This Outcome 
Only one study (Khan 2017) evaluated 25(OH)D levels > 40 units at 10 weeks.  
b. Studies that Found a Positive or Negative Effect 
In this single study, the patients who received supplementation were 40 times more 
likely to have 25(OH)D levels > 40 units at 10 weeks than control patients (OR=40.53; 
95% CI 15.71-104.52).  
c. Pooled Effects 
We did not pool these effects due to only one study being identified. However, this 
study identified 59 individuals reaching optimal 25(OH)D levels out of 70 participants with 
supplementation, and only 9 reaching optimal levels out of 77 control participants.  
5. Greater than 40 Units at 16 Weeks 
The 25(OH)D levels greater than 40 units at 16 weeks measurements taken from 
studies that provided this information are described here. 
a. Number of Studies that Estimated This Outcome 
We identified two studies which evaluated 25(OH)D levels > 40 units at 16 weeks. 
These two studies are Iniesta(a) et al. (2016), and Khan et al. (2010).  
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b. Studies that Found a Positive or Negative Effect
For this outcome, we found opposing effects. We found a positive effect on calcium 
and vitamin D supplementation for improving 25(OH)D levels > 40 units at 16 weeks in 
Khan et al. (2010) (OR=43.62; 95% CI 2.01-945.91), however a non-significant reduced 
effect in Iniesta(a) et al. (2016) (OR=0.29; 95% CI 0.01-6.39).  
c. Pooled Effects
We pooled these two studies as seen in Figure 7, and the RE model yielded a non-
significant pooled OR of 3.58 (95% CI 0.03- 490.21). However, the FE model yielded a 
non-significant pooled OR as well of 2.91 (95% CI 0.73-11.58). A total of 54 participants 
achieved the desirable outcome among the 58 participants with supplementation. 
Moreover, 11 control participants achieved the outcome out of the 14 control patients. 
Heterogeneity between the two studies was significant (p=0.02) and substantial 
heterogeneity was noted (I² = 80%).  
Figure 7. 25(OH)D levels > 40 units at 16 weeks analysis from 
observational studies. Adapted from Higgins and Green (2011). 
6. Greater than 40 Units at 24 Weeks
The 25(OH)D levels greater than 40 units at 24 weeks measurements taken from 
studies that provided this information are described here. 
a. Number of Studies that Estimated This Outcome
Only one study (Khan 2017) evaluated 25(OH)D levels > 40 units at 24 weeks. 
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b. Studies that Found a Positive or Negative Effect 
In this single study, there was positive effect on calcium and vitamin D 
supplementation for improving 25(OH)D levels > 40 units at 24 weeks in participants from 
this study.  
c. Pooled Effects 
This study identified 59 individuals reaching optimal 25(OH)D levels at 24 weeks 
out of 70 participants with supplementation, and only 8 reaching optimal levels out of 77 
control participants.  
C. SUBGROUP ANALYSES SECTION 
In the final section of this chapter, we find some different comparisons among some 
or all the studies, according to the criteria in question. 
1. Lumbar Spine BMD: Observational Studies (High/Medium vs. low 
Risk of Bias) 
This subgroup of observational studies comparing according to their level of risk 
of bias per NOS, was the only subgroup possible out of all of our studies. This is because 
there was no other measurements section to have at least two different studies that are 
purely observational. 
a. Number of Studies that Estimated This Outcome 
Four studies in this subgroup performed lumbar spine BMD measurements and 
were pooled together according to their risk of bias per NOS outcomes from Table 1. The 
objective is to analyze for any significant outcomes between the two groups.  
(1) High/medium risk of bias studies 
• Schnabel et al. (2013) 
(2) Low risk of bias studies 
• calcium vs. low calcium supplementation groups from Jain et al. (2017) 
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• vitamin D vs. low vitamin D supplementation groups from Jain et al. 
(2017) 
• Leonova et al. (2015) 
b. Studies that Found a Positive or Negative Effect 
In this case, there were no studies that found a positive effect on calcium and 
vitamin D supplementation for improving bone mineral density in the lumbar spine BMD 
measurements.  
c. Pooled effect. SMD or OR, p-value, and I² est. (heterogeneity)? 
Only one study is part of the high/medium risk level of bias subgroup, as displayed 
in Figure 8, show a SMD of 0.56 with a CI of [-0.19, 1.30] that come from having a total 
of 25 participants with supplementation, and 10 participants from a control treatment group 
such as a placebo.  
The three studies pooled together to form the low risk level of bias, as displayed in 
Figure 8, show a SMD of 0.10 with a CI of [-0.15, 0.35] that come from having a total of 
107 participants with supplementation, and 145 participants from a control treatment group 
such as a placebo.  
Their pooled FE has a SMD of 0.15, and their RE has the same values. Their test 
for overall FE and RE had a p-value of 0.23, which is not significant. However, their I² for 
heterogeneity was 0%, which is not significant.  
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Footnotes: (in order of appearance) Jain 2017(1): calcium vs. low calcium supplements 
comparison. Jain 2017(2): vitamin D vs. low vitamin D supplements comparison.  
Figure 8. Lumbar spine BMD analysis from subgroup made of 
observational studies between high/medium risk vs. low risk of 
bias. Adapted from Higgins and Green (2011). 
2. Total BMD: Observational Studies (High/Medium vs. Low Risk of 
Bias) 
This subgroup of observational studies comparing  
a. Number of Studies that Estimated This Outcome 
We pooled six studies in this subgroup and performed total BMD measurements 
according to their risk of bias per Newcastle-Ottawa outcomes from Table 1. The objective 
is to analyze for any significant outcomes between the two groups (see Figure 9).  
(1) High/medium risk of bias studies 
• Schneider et al. (2004) boys subgroup 
• Schneider et al. (2004) girls subgroup 
(2) Low risk of bias studies 
• calcium vs. low calcium supplementation groups from Jain et al. (2017) 
• vitamin D vs. low vitamin D supplementation groups from Jain et al. 
(2017) 
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b. Studies that Found a Positive or Negative Effect 
In this case, there was only one study out of the high/medium risk of bias subgroup 
that found a significant effect, which was to favor calcium and vitamin D supplementation 
for improving bone mineral density in the total BMD measurements. Not all other studies 
were significant although one had a slight negative effect; however, the overall is also not 
significant. 
c. Pooled Effect. SMD or OR, p-value, and I² est. (Heterogeneity)? 
The pooled FE model yielded a significant pooled OR with a SMD of 0.39 with a 
CI of [0.15, 0.62], however their RE model yielded a non-significant pooled OR and has a 
SMD of 0.56 with a CI of [-0.43, 1.55]. Their I² came out as 94%, which is highly 
significant for heterogeneity and with a p-value of less than 0.01.  
 
Footnotes: (in order of appearance) Schneider 2004(1): boys. Schneider 2004(2): girls. Jain 
2017(1): calcium vs. low calcium supplements comparison. Jain 2017(2): vitamin D vs. low 
vitamin D supplements comparison.  
Figure 9. Total BMD analysis from subgroup made of observational studies 
between high/medium risk vs. low risk of bias. Adapted from 
Higgins and Green (2011). 
3. Pediatric vs. Adult Studies 
This subgroup analysis is made of studies and sub studies that contain the lumbar 
spine BMD measurements, which we then pooled together according to their patient 
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classification of either pediatric or adult. The objective is to analyze for any significant 
outcomes between the two classification groups.  
a. Number of Studies that Estimated This Outcome 
We pooled four studies in this subgroup and performed lumbar spine BMD 
measurements to analyze for any significant outcome (see Figure 10).  
(1) Pediatric studies 
• calcium vs. low calcium supplementation groups from Jain et al. (2017) 
• vitamin D vs. low vitamin D supplementation groups from Jain et al. 
(2017) 
(2) Adult studies 
• Leonova et al. (2015) 
• Schnabel et al. (2013) 
b. Studies that Found a Positive or Negative Effect 
In this case, there was no study that found a positive or even negative effect on 
calcium and vitamin D supplementation for improving bone mineral density in the lumbar 
spine BMD measurements. Although no studies were significant, most had a slight positive 
effect toward supplementation; however, the overall is not significant. 
c. Pooled Effect. SMD or OR, p-value, and I² est. (Heterogeneity)? 
Their pooled FE model yielded a non-significant pooled OR with a SMD of 0.15, 
and their RE model also yielded a non-significant pooled OR with the same SMD. 
Furthermore, their I² for heterogeneity came out as 0%, which is not significant and shows 
its p-value of 0.60.  
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Footnotes: (numbered in order of appearance) Jain 2017(1): calcium vs. low calcium 
supplements comparison. Jain 2017(2): vitD vs. low vitD supplements comparison. 
Figure 10. Lumbar spine BMD analysis from subgroup made of 
observational studies between pediatric and adult study groups. 
Adapted from Higgins and Green (2011). 
D. PUBLICATION BIAS ASSESSMENT 
Due to a small number of identified publications evaluating the effect of 
supplementation on various bone outcomes, we were unable to adequately assess 
publication bias. For added clarity, we created a funnel plot to evaluate graphically with 
some validity, the studies’ publication bias. An example of this is noted in Figure 11. In 
the figure, we can see there are four visible studies outside the contour lines of the funnel, 
which form a shape as of a triangle. These four studies are significantly different from the 
rest due to their smaller standard error and smaller SMD or plainly a larger SMD overall.  
We found useful data for our study in three of the four RCT studies and so only 
those three are shown here. Two of these are outside the funnel delineated by red squares. 
Kaste et al. (2014) is one of these two and it stands outside the intervals of the funnel 
mainly due to its sample size large enough and having an outcome favorable to controls, 
which leaned its SMD into the left, and having a small spread of SE as well, made it be 
outside the overall SMD for the group. Khan et al. (2017) is the other RCT study outside 
the funnel located on the right. This study found significant findings on its outcomes 
favoring supplementation, however, the reason this RCT stands out to the far right is that 
it was the only RCT that contained vitamin D outcomes. Hence, there was no true effect 
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comparison with this RCT so the reason of the effect that it shows a different outcome 
value. 
The other two studies outside the funnel are actually two sub studies from the same 
study by Schneider et al. (2004). This study did analysis on a boys’ group and analysis on 
a girls group. Their findings were that the boys’ group had significant evidence on positive 
effects on supplementation, while the opposite was found for the girls, as previously 
explained. Schneider et al. was the only observational study we found containing 
significant findings, hence the reason it stands outside the SMD interval of the rest of the 
group. However, our NOS scale to contain high-risk level of bias assessed Schneider et al. 
study. 
Although it is important to note that there is bias in this assessment as many of these 
studies contain different types of measurements as seen previously that for BMD as well 
as for the levels of 25(OH)D, there are different scales. More importantly, we are showing 
in this graph both RCT and observational studies. Therefore, the figure in this section is 
for illustration purposes only and not to make a decision based on its output.  
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Figure 11. Funnel displaying observational and RCT studies. Red squares are 
RCT and blue circles are observational studies. 
E. QUALITY OF EVIDENCE EVALUATION 
We also evaluated the quality of evidence provided by the analysis made via the 
GRADEpro GDT application (GRADEpro GDT, 2015). For each of the 14 studies, we 
evaluated each outcome and its pooled effect for assessing quality of evidence. The 
GRADEpro approach offers reviewers an overview on the certainty of the evidence from 
the outcomes. It is a tool to make informed decisions regarding how each study is 
influenced through its certainty and its findings. GRADEpro outcomes have four levels of 
certainty ranging from very low confidence to high. 
All the RCT studies result in a high certainty score from GRADEpro while the 
observational studies range from very low to low certainty mostly due to study design 
deficits. Therefore, all these outcomes with estimates produced by observational studies 
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were determined to be very low quality, except for lumbar spine, which was the only 
outcome we determined to have low quality via GRADEpro. Usually upon submitting an 
assessment in GRADEpro for an observation study or any study that will not have high 
level of certainty, the system will ask for submitting a note or comment so others can see 
a description of why a certain study had lower certainty level. In our studies, some of the 
comments submitted for the observational studies were:  
1. Performed with voluntary participants 
2. Ten of the participants did not complete the treatment, as it was not 
specified in the study. In addition, one other male participant mentioned is 
unknown of his status throughout the study assessments. 
3. Among eligible ALL survivors identified for the study, these patients 
consented to receive treatment, therefore not randomized. 
4. Recruitment of participants from the Chernobyl accident between 15 
January 2007 and 23 December 2010 lacked randomization. 




We performed a meta-analysis to determine whether taking vitamin D and/or 
calcium supplementation enhances BMD for oncology patients. As of today, there is no 
consensus among medical researchers on whether this supplementation at all affects bone 
health outcomes in cancer patients. Currently, Tricare does not cover multivitamins or 
multiminerals, and its online drug formulary only lists one type of vitamin D out of 44 
different vitamin D formulas as eligible for coverage although they have a disclaimer for 
coverage of medically necessary and proven medical services. This lack of coverage along 
with the uncertainty of significant improvement for BMD in cancer patients inspired us to 
perform a systematic review of all relevant studies to find a better predictor.  
We first needed to find as many studies as possible. Randomized controlled trials 
were best, but we also considered any non-randomized clinical study that met thesis 
inclusive criterion, so a meta-analysis would be viable. The search started with over 700 
study abstracts of which, by using the PICO framework analysis, we found 40 potentially 
viable studies, and, finally, after performing a full study analysis, chose 14. Those 
disqualified were mostly non-randomized studies, and/or lacked some or most of the 
thesis’s inclusion criteria. The 14 studies include four RCTs and ten observational studies. 
This selection flow can be seen in Figure 1. 
Observational studies, due to their nature of the lack of randomization, went 
through additional screening to measure their level of risk of bias. Observational studies 
carry a high risk of bias throughout all phases of development, compared to RCT studies, 
inherently less biased due to randomization. We assessed this risk of bias level according 
to the NOS assessment. This risk of bias assessment helped analyze each observational 
study by looking at key elements where risk of bias could be inherent, and thus converting 
this qualitative analysis into a numeric score or scaled metric (as seen in Table 1), which 
helps assess the level of risk of bias according to the criteria set by the reviewer. This 
criteria was set as a scale in which we classified each observational study into a high/
medium risk of bias, which transferred from those studies that had the lowest numeric score 
starting from six and below, and into a low risk of bias analysis for those studies that had 
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the topmost numeric scores starting from seven up to the nine total points possible. This 
NOS assessment tool helped determine that, according to our criteria, four observational 
studies had a low risk of bias while the other six studies had a medium to high risk of bias. 
A good comparison analysis of the difference of effectiveness within these two groups can 
be seen in two different analyses illustrated in Figure 8 and Figure 9. 
We met challenges including a core challenge that most of the studies had their own 
distinctive way of doing analysis while others described somewhat different outcome 
measurements and thus different reporting measurements, or, even worse, a lack of 
reporting on some of the important measurements for our study. We met this challenge 
both by carefully selecting only 14 studies of the 700, looking for common quantitative, 
rather than qualitative factors. We included studies that shared some common metrics: 
measurements of the lumbar spine BMD, hip BMD, proximal femur BMD, total BMD, 
25(OH)D levels at various lengths of time, and 25(OH)D levels over 40 units at various 
lengths of time. To overcome some differences in reporting outcomes, we used a SMD as 
a base comparison for the entire continuous unit-based analyses and an OR effect measure 
as a baseline for the dichotomous unit-based analyses.  
Additional statistical analyses performed with the studies included examining their 
pooled effect and the variation across the studies. We also compared intervention effect 
estimates by looking at their RE and FE, as well as looking at their heterogeneity effect 
overall with probability values for significance between studies if more than one study was 
involved. In FE models, all studies in a meta-analysis share common estimator (a common 
true effect size). The RE model assumes the studies are drawn from populations that are 
different (in turn, affecting effect estimates). The effect of heterogeneity was qualitatively 
assessed using the I2 statistic as follows: between 30% and 60% considered moderate 
heterogeneity, 50% to 90% considered substantial heterogeneity, and 75% to 100% 
considered the effect as a high level of heterogeneity.  
A significant finding in each analysis was noted if an SMD’s 95% confidence 
interval was entirely above or below zero. Anything outside this CI is reported as not being 
a significant finding or as not having enough evidence for a specific parameter being 
statistically significant at a 95% confidence level. In our analysis, there was no significant 
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heterogeneity found in the lumbar spine BMD analyses (RCTs and observational), also in 
the lumbar spine BMD with subgroups of high/medium risk of bias vs. low risk of bias 
analysis, and lastly in the lumbar spine BMD analysis from the subgroup analysis made of 
observational studies between pediatric and adult study groups. However, significant 
heterogeneity was found in the total BMD analysis made of observational studies (high 
level heterogeneity), also in the 25(OH)D levels > 40 units at 24 weeks analysis (high 
level), and, lastly, in the total BMD analysis from subgroup made of observational studies 
between high/medium risk vs. low risk of bias (high level). 
Results obtained from this meta-analysis produced no significant statistical 
evidence that the supplements in question improve BMD. From the RCT studies, only one 
was found to have significant evidence about supplementation making an impact on bone 
health (Khan et al. (2017)), according to its outcome on 25(OH)D levels. From the 
observational studies, just three out of the ten studies had some significant evidence on the 
use of supplementation making positive impact: 
• Schnabel et al. (2013), in their hip BMD assessment 
• Schneider et al. (2004) (boys’ group), in their total BMD assessment (as 
seen in Figure 6), and  
• Khan et al. (2010), in their 25(OH)D levels > 40 units at 16 weeks 
assessment (as seen in Figure 7) 
The remainder of the observational studies demonstrated neither positive nor negative 
significant outcomes.  
Our results found in this this thesis come with a few caveats. One limitation was 
such that there is not much published evidence for pediatrics, especially RCTs. The lack of 
RCTs in our research likely diminishes the power of evidence or the statistical significance, 
which is what this thesis is trying to demonstrate. The particularly narrowed search criteria 
considering our specific interventions and bone health as outcome, produced lower than 
expected studies to choose from as seen in Figure 1. Further research will most likely 
strengthen this meta-analysis and its power of predictability of findings, if any. 
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One of our findings does show a slight incline towards favoring supplementation 
for adults as well as for children, especially by looking at the subgroup analyses section in 
this thesis and looking at Figures 8–10. Although, again, no subgroup analysis in this thesis 
found any significant findings at a 95% confidence level regarding supplementation effects 
on bone health. An example of the included studies can be seen in Figure 11. Although it 
is not best to mix RCTs with observational studies, Figure 11 can be helpful as an overall 
comparison for possible effects. Keeping in mind, many of these studies are in different 
areas of the scale because they contain different areas of measurements according to their 
specific study. 
As a last step, we looked at evaluating the quality of the evidence with the assistance 
of an analysis software called GRADEpro GDT (GRADEpro GDT, 2015). The 
GRADEpro approach gave us an overview on the certainty of the evidence from the 
outcomes of all of our studies used in this thesis. We used this as a tool to make informed 
decisions regarding how each study is influenced through its certainty and its findings we 
obtained from them. GRADEpro outcomes have four levels of certainty. These levels go 
from very low certainty (i.e., very low confidence) to high certainty, which means we have 
confidence in that estimate of the effect. 
All the RCT studies result in GRADEpro having a high level of certainty, while all 
other studies such as the observational studies have some other level of certainty. 
Therefore, all these outcomes with estimates produced by observational studies were 
determined to be very low quality, except for lumbar spine, which we assessed as simply 
low quality per our GRADEpro quality of evidence assessment. This is a great tool that 
policymakers can use to look at how all the studies ranked in terms of certainty of the 
evidence and its importance overall in the study. 
In conclusion, many estimates show increases/benefits for supplementation being 
effective for BMD changes, but few were statistically significant. Perhaps future studies 
should be better driven to detect differences, and/or also larger sample sizes could prove to 
be a great benefit. 
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These findings could help as support for additional evidence for clinicians and 
healthcare policy makers for decision-making and making recommendations for cancer 
patients. These findings should also be considered in the context that these supplements 
are relatively cheap and not harmful. However, their benefits are also not evidenced. We 
strongly encourage further research to help make conclusions stronger; the results of this 
thesis hopefully can serve as a basis for additional clarity, further analysis, and 
consideration for the DoD P&T committee. This committee controls the formulary that all 
DoD beneficiaries use. Therefore, this thesis offers an effective basis from which the 
committee can study the effects of vitamin D and calcium supplements to increase BMD 
for oncology patients.  
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APPENDIX A. CHARACTERISTICS - EXCLUDED STUDIES 
The following studies were excluded for the reasons noted. Following full-text 
screening, we excluded 29 studies from our analysis for not meeting satisfactory criteria. 
Atkinson et al. (1989) children picked consecutively. No RCTs done.  
Bacchetta, Ranchin, Dubourg, and Cochat (2010) study does not have RCT. 
Vitamin D perspectives on health effects with pediatric suggested recommendations.  
Beebe et al. (2017) analyzed outcomes in HSCT subjects. No RCT, vitD/calcium 
treatment, placebo groups.  
Bilariki et al. (2010) did an exploratory study that examined 52 consecutive cancer 
survivor patients for BMD and vitamin D deficiency. No RCT as it was consecutive 
selection. 
Bryant, Worthington, and Parsons (2009) performed a qualitative review in a 
group of children with leukemia during their treatment of osteoporosis/osteopenia. 
Cashman (2007) demonstrates classical effects of vitamin D. No mention of 
leukemia, etc.  
Cohen, Wakefield, and Cohn (2016) performed a review of nutritional 
interventions  
Cox, McLaughlin, Rai, Steen, and Hudson (2005) has no RCTs. Only measures 
health behaviors. 
El-Ziny et al. (2007) study with no RCTs done. Conducted a study on 
consecutively recruited children to compare with healthy controls for low bone mass 
comparisons after chemotherapy treatment. 
Esbenshade et al. (2015) did a retrospective medical records abstraction. No 
RCTs. 
Garland et al. (1990) study does not have children nor placebos involved.  
Hellstrom et al. (1988) does not have children nor placebos involved, etc.  
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Helou et al. (2014) comparison of 25-OH D levels to different healthy group 
populations. 
Henderson, Madsen, Davis, and Gold (1998) no RCTs. Selection method absent 
other than being pediatric cancer patients undergoing chemotherapy treatments. 
Revuelta Iniesta et al. (2016) is a review.  
Krishnamoorthy, Freeman, Bernstein, Lawrence, and Rodd (2004) no RCTs. 
Retrospective and prospective data collection from medical records for selection of 
participants. 
Mays et al. (2011) is only assessing dietary intake of calcium.  
Mimouni and Shamir (2009) conducted a qualitative review in vitamin D 
supplementation.  
Moreno, Valtueña, Pérez-López, and González-Gross (2011) conducted a 
vitamin D meta-analysis of observational studies regarding its health effects by having low 
dosage concentrations.  
Reisi, Iravani, Raeissi, and Kelishadi (2015) case-control study to analyze the 
status of vitamin D and BMD in long-term survivors of pediatric ALL. Data was collected 
via questionnaire and medical charts as well as questions from parents. Blood samples were 
taken from participants to provide biochemical analysis. No intervention, RCTs 
J de Schepper, Hachimi-Idrissi, Louis, Maurus, and Otten (1994) study has no 
RCTs, control or placebo groups nor nutritional intervention.  
Schulte and Beelen (2004) study does not include pediatric subjects, placebos, etc.  
Sinha, Avery, Turner, Bailey, and Cheetham (2011) cross-sectional 
observational study. A total of 121 children were then enrolled in the study and serum 
concentrations of 25-OH D were taken and analyzed for all cases and control groups. No 
intervention done. 
De Smedt et al. (2017) study contains no pediatric subjects, ALL, or BMD.  
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Swiatkiewicz et al. (2003) evaluated for BMD and bone mineral metabolism with 
examinations performed twice. Prospective study. No RCTs. 
Wacker and Holiack (2013) performed a vitamin D observational study on its 
effects on maintaining a healthy skeletal and extraskeletal (Wacker and Holiack, 2013).  
Wasilewski-Masker et al. (2008) conducted a review of the literature regarding 
BMD deficits in survivors of childhood cancer, which is not a RCT.  
Zeeb and Greinert (2010) developed a review article regarding vitamin D within 
cancer prevention. Not a RCT analysis.  
Zittermann and Gummert (2010) developed a well extensive review article on 
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APPENDIX B. GRADEpro QUALITY OF EVIDENCE OUTCOMES 
This appendix data was obtained by analyzing this thesis studies with GRADEpro 
GDT (2015).  
Certainty assessment № of patients Effect 
Certainty Importance № of 
studies Study design 
Risk of 









Lumbar Spine BMD: RCT 
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Total BMD: RCT 
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25OHD levels > 40 at 24 weeks: RCT 






















Lumbar Spine BMD: Observational 
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Certainty assessment № of patients Effect 
Certainty Importance № of 
studies Study design 
Risk of 
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250HD levels at 4 weeks: Observational 
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Lumbar Spine BMD: Observational (High/Medium vs. Low Risk of Bias) - High/Medium Risk of Bias 
















Lumbar Spine BMD: Observational (High/Medium vs. Low Risk of Bias) - Low Risk of Bias 
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Certainty assessment № of patients Effect 
Certainty Importance № of 
studies Study design 
Risk of 
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Lumbar spine BMD: Pediatric vs. adult studies - Pediatrics 














Lumbar spine BMD: Pediatric vs. adult studies - Adults 















a. Performed with voluntary participants.  
b. Ten of these participants did not complete the treatment, as it is not specified in the study. In 
addition, one other male participant mentioned as well, is unknown of his status throughout the 
study.  
c. Among eligible ALL survivors identified for the study, these patients consented for 
participation. Not randomized.  
d. Recruitment of participants from the Chernobyl accident between 15 January 2007 and 23 




THIS PAGE INTENTIONALLY LEFT BLANK  
57 
LIST OF REFERENCES 
American Cancer Society. (2018). Cancer Facts and Figures 2018. American Cancer 
Society, 1–71. https://doi.org/10.1182/blood-2015-12-687814 
Anglemyer, A., Agrawal, A. K., & Rutherford, G. W. (2014). Treatment of Kaposi 
sarcoma in children with HIV-1 infection. Cochrane Database of Systematic 
Reviews, 2014(1). https://doi.org/10.1002/14651858.CD009826.pub2 
Anglemyer, A., Horvath, H., & Bero, L. (2014). Healthcare outcomes assessed with 
observational study designs compared with those assessed in randomized trials 
(Review). Cochrane Database of Systematic Reviews 2014, Art. No.:(4), 44. 
https://doi.org/10.1002/14651858.MR000034.pub2 
Anglemyer, A., Horvath, T., & Rutherford, G. (2014). The accessibility of firearms and 
risk for suicide and homicide victimization among household members. Annals of 
Internal Medicine. https://doi.org/10.7326/M13-1301 
Atkinson, S. A., Fraher, L., Gundberg, C. M., Andrew, M., Pai, M., & Barr, R. D. (1989). 
Mineral homeostasis and bone mass in children treated for acute lymphoblastic 
leukemia. The Journal of Pediatrics, 114(5), 793–800. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/2785592 
Bacchetta, J., Ranchin, B., Dubourg, L., & Cochat, P. (2010). Vitamine D : un acteur 
majeur en sante´ ? [Vitamin D revisited: A cornerstone of health? J.]. Archives de 
Pédiatrie : Organe Officiel de La Sociéte Française de Pédiatrie, 17(12), 1687–
1695. https://doi.org/10.1016/j.arcped.2010.09.003 
Beebe, K., Magee, K., McNulty, A., Stahlecker, J., Salzberg, D., Miller, H., … Ngwube, 
A. (2017). Vitamin D deficiency and outcomes in pediatric hematopoietic stem 
cell transplantation. Pediatric Blood & Cancer, 65(August 2017). https://doi.org/
10.1002/pbc.26817 
Bilariki, K., Anagnostou, E., Masse, V., Elie, C., Grill, J., Valteau-Couanet, D., … Polak, 
M. (2010). Low bone mineral density and high incidences of fractures and 
vitamin D deficiency in 52 pediatric cancer survivors. Hormone Research in 
Paediatrics, 74(5), 319–327. https://doi.org/10.1159/000313378 
Bryant, M. L., Worthington, M. A., & Parsons, K. (2009). Treatment of osteoporosis/
osteopenia in pediatric leukemia and lymphoma. Annals of Pharmacotherapy, 
43(4), 714–720. https://doi.org/10.1345/aph.1L567 
Cashman, K. D. (2007). Vitamin D in childhood and adolescence. Postgraduate Medical 
Journal, 83(978), 230–235. https://doi.org/10.1136/pgmj.2006.052787 
58 
Cohen, J. E., Wakefield, C. E., & Cohn, R. J. (2016). Nutritional interventions for 
survivors of childhood cancer. Cochrane Database of Systematic Reviews, (8), 
Art. No.: CD009678. https://doi.org/10.1002/14651858.CD009678.
pub2.www.cochranelibrary.com 
Cox, C. L., McLaughlin, R. A., Rai, S. N., Steen, B. D., & Hudson, M. M. (2005). 
Adolescent survivors: A secondary analysis of a clinical trial targeting behavior 
change. Pediatric Blood & Cancer, 45(2), 144–154. https://doi.org/10.1002/
pbc.20389 
De Smedt, J., Van Kelst, S., Boecxstaens, V., Stas, M., Bogaerts, K., Vanderschueren, D., 
… Garmyn, M. (2017). Vitamin D supplementation in cutaneous malignant 
melanoma outcome (ViDMe): A randomized controlled trial. BMC Cancer, 
17(562). https://doi.org/10.1186/s12885-017-3538-4 
Demirsoy, U., Sarper, N., Gelen, S. A., Zengin, E., Kum, T., & Demir, H. (2017). The 
association of oral vitamin D and calcium supplementation with bone mineral 
density in pediatric acute lymphoblastic leukemia patients. Journal of Pediatric 
Hematology Oncology, 39(4), 287–292. https://doi.org/10.1097/
MPH.0000000000000797 
Dersimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Statistics in 
Medicine, 188, 177–188. https://doi.org/10.1016/0197-2456(86)90046-2 
Díaz, P. R., Neira, L. C., Fischer, S. G., Teresa Torres, M. C., Milinarsky, A. T., 
Giadrosich, V. R., … Casanova, D. M. (2008). Effect of 1,25(OH)2—vitamin D 
on bone mass in children with acute lymphoblastic leukemia. Journal of Pediatric 
Hematology/Oncology, 30(1), 15–19. https://doi.org/10.1097/
MPH.0b013e318159a522 
El-Ziny, M. A., Al-Tonbary, Y. A., Salama, O. S., Bakr, A., Al-Marsafawy, H., & 
Elsharkawy, A. A. (2007). Low bone mass in children with malignant lymphoma. 
Pediatric Hematology and Oncology, 24(8), 577–585. https://doi.org/10.1080/
08880010701640275 
Esbenshade, A. J., Sopfe, J., Zhao, Z., Li, Z., Campbell, K., Simmons, J. H., & Friedman, 
D. (2015). Screening for Vitamin D Insufficiency in Pediatric Cancer Survivors. 
Pediatric Blood Cancer, 61(4), 723–728. https://doi.org/10.1002/
pbc.24844.Screening 
Garland, F. C., Shaw, E., Gorham, E. D., Garland, C. F., White, M. R., & Sinsheimer, P. 
J. (1990). Incidence of leukemia in occupations with potential electromagnetic 
field exposure in United States Navy personnel. American Journal of 
Epidemiology, 132(2), 293–303. 
59 
Goldberg, J., Eisen, S. A., True, W. R., & Henderson, W. G. (1992). Health effects of 
military service lessons learned from the Vietnam experience. Annals of 
Epidemiology, 2(6), 841–853. https://doi.org/10.1016/1047-2797(92)90078-5 
GRADEpro GDT. (2015). GRADEpro Guideline Development Tool [Software]. 
McMaster University (developed by Evidence Prime, Inc.). Retrieved from 
gradepro.org 
Guise, T. A. (2006). Bone Loss and Fracture Risk Associated with Cancer Therapy. The 
Oncologist, 11(10), 1121–1131. https://doi.org/10.1634/theoncologist.11-10-1121 
Gurney, J. G., Kaste, S. C., Liu, W., Srivastava, D. K., Chemaitilly, W., Ness, K. K., … 
Hudson, M. M. (2014). Bone mineral density among long-term survivors of 
childhood acute lymphoblastic leukemia: Results from the St. Jude Lifetime 
Cohort Study. Pediatric Blood & Cancer, 61(7), 1270–1276. https://doi.org/
10.1002/pbc.25010 
Hedges, L. V., & Olkin, I. (1985). Statistical methods for meta-analysis (1st ed.). 
Orlando: Academic Press, Inc. https://doi.org/10.2307/1164953 
Hellstrom, E., Robert, K. H., Gahrton, G., Mellstedt, H., Lindemalm, C., Einhorn, S., … 
Samuelsson, J. (1988). Therapeutic effects of low-dose cytosine arabinoside, 
alpha-interferon, 1 alpha-hydroxyvitamin D3 and retinoic acid in acute leukemia 
and myelodysplastic syndromes. European Journal of Haematology, 40(5), 449–
459. 
Helou, M., Ning, Y., Yang, S., Irvine, P., Bachmann, L. M., Godder, K., & Massey, G. 
(2014). Vitamin d deficiency in children with cancer. Journal of Pediatric 
Hematology/ Oncology, 36(3), 212–217. https://doi.org/10.1097/
MPH.0b013e31829f3754 
Henderson, R. C., Madsen, C. D., Davis, C., & Gold, S. H. (1998). Longitudinal 
evaluation of bone mineral density in children receiving chemotherapy. Journal of 
Pediatric Hematology/Oncology, 20(4), 322–326. https://doi.org/10.1097/
00043426-199807000-00008 
Higgins, J., & Green, S. (Eds.). (2011). Cochrane handbook for systematic reviews of 
interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 
Retrieved from www.cochrane-handbook.org 
Iniesta, R. R., Paciarotti, I., Davidson, I., McKenzie, J. M., Brand, C., Chin, R. F. M., … 
Wilson, D. C. (2016). 5-Hydroxyvitamin D concentration in paediatric cancer 
patients from Scotland: A prospective cohort study. British Journal of Nutrition, 
116(11), 1926–1934. https://doi.org/10.1017/S0007114516004074 
60 
J de Schepper, Hachimi-Idrissi, S., Louis, O., Maurus, R., & Otten, J. (1994). Bone 
metabolism and mineralisation after cytotoxic chemotherapy including 
ifosfamide. Archives of Disease in Childhood, 71, 346–348. 
Jain, S., Jain, S., Kapoor, G., Virmani, A., & Bajpai, R. (2017). No impact of disease and 
its treatment on bone mineral density in survivors of childhood acute 
lymphoblastic leukemia. Pediatric Blood & Cancer, 64. https://doi.org/10.1002/
pbc.26271 
Kadan-Lottick, N., Marshall, J. A., Barón, A. E., Krebs, N. F., Hambidge, K. M., & 
Albano, E. (2001). Normal bone mineral density after treatment for childhood 
acute lymphoblastic leukemia diagnosed between 1991 and 1998. Journal of 
Pediatrics, 138(6), 898–904. https://doi.org/10.1067/mpd.2001.113102 
Kaste, S. C., Qi, A., Smith, K., Surprise, H., Lovorn, E., Boyett, J., … Ness, K. K. 
(2014). Calcium and cholecalciferol supplementation provides no added benefit to 
nutritional counseling to improve bone mineral density in survivors of childhood 
acute lymphoblastic leukemia (ALL). Pediatric Blood and Cancer, 61(5), 885–
893. https://doi.org/10.1002/pbc.24882 
Kaste, S. C., Rai, S. N., Fleming, K., McCammon, E. A., Tylavsky, F. A., Danish, R. K., 
… Hudson, M. M. (2006). Changes in bone mineral density in survivors of 
childhood acute lymphoblastic leukemia. Pediatric Blood & Cancer, 46(1), 77–
87. https://doi.org/10.1002/pbc.20553 
Khan, Q. J., Kimler, B. F., Reddy, P. S., Sharma, P., Klemp, J. R., Nydegger, J. L., … 
Fabian, C. J. (2017). Randomized trial of vitamin D3 to prevent worsening of 
musculoskeletal symptoms in women with breast cancer receiving adjuvant 
letrozole. The VITAL trial. Breast Cancer Research and Treatment, 166(2), 491–
500. https://doi.org/10.1007/s10549-017-4429-8 
Khan, Q. J., Reddy, P. S., Kimler, B. F., Sharma, P., Baxa, S. E., O’Dea, A. P., … 
Fabian, C. J. (2010). Effect of vitamin D supplementation on serum 25-hydroxy 
vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole 
treatment for breast cancer. Breast Cancer Research and Treatment, 119(1), 111–
118. https://doi.org/10.1007/s10549-009-0495-x 
Krishnamoorthy, P., Freeman, C., Bernstein, M. L., Lawrence, S., & Rodd, C. (2004). 
Osteopenia in children who have undergone posterior fossa or craniospinal 
irradiation for brain tumors. Archives of Pediatrics and Adolescent Medicine, 
158(5), 491–496. https://doi.org/10.1001/archpedi.158.5.491 
Leonova, T. A., Drozd, V. M., Saenko, V. A., Mine, M., Biko, J., Rogounovitch, T. I., … 
Yamashita, S. (2015). Bone mineral density in treated at a young age for 
differentiated thyroid cancer after Chernobyl female patients on TSH-suppressive 
therapy receiving or not Calcium-D3 supplementation. Endocrine Journal, 62(2), 
173–182. https://doi.org/10.1507/endocrj.EJ14-0408 
61 
Mays, D., Black, J. D., Mosher, R. B., Heinly, A., Shad, A. T., & Tercyak, K. P. (2011). 
Efficacy of the survivor health and resilience education (SHARE) program to 
improve bone health behaviors among adolescent survivors of childhood cancer. 
Annals of Behavioral Medicine, 42(1), 91–98. https://doi.org/10.1007/s12160-
011-9261-5.Efficacy 
Mimouni, F. B., & Shamir, R. (2009). Vitamin D requirements in the first year of life. 
Current Opinion in Clinical Nutrition and Metabolic Care, 12(3), 287–292. 
https://doi.org/10.1097/MCO.0b013e32832a1329 
Modan-Moses, D., Pinhas-Hamiel, O., Munitz-Shenkar, D., Temam, V., Kanety, H., & 
Toren, A. (2012). Vitamin D status in pediatric patients with a history of 
malignancy. Pediatric Research, 72(6), 620–624. https://doi.org/10.1038/
pr.2012.131 
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., Altman, D., Antes, G., … Tugwell, P. 
(2009). Preferred reporting items for systematic reviews and meta-analyses: The 
PRISMA statement. PLoS Medicine, 6(7). https://doi.org/10.1371/
journal.pmed.1000097 
Moreno, L. A., Valtueña, J., Pérez-López, F., & González-Gross, M. (2011). Health 
effects related to low vitamin D concentrations: Beyond bone metabolism. Annals 
of Nutrition and Metabolism, 59(1), 22–27. https://doi.org/10.1159/000332070 
Peppone, L. J., Huston, A. J., Reid, M. E., Rosier, R. N., Zakharia, Y., Trump, D. L., … 
Morrow, G. R. (2011). The effect of various vitamin D supplementation regimens 
in breast cancer patients. Breast Cancer Research and Treatment, 127(1), 171–
177. https://doi.org/10.1007/s10549-011-1415-4 
Peterlik, M., Grant, W. B., & Cross, H. S. (2009). Calcium, vitamin D and cancer. 
Anticancer Research, 29(9), 3687–3698. https://doi.org/VL-29 
Rai, S. N., Hudson, M. M., McCammon, E., Carbone, L., Tylavsky, F., Smith, K., … 
Kaste, S. (2008). Implementing an intervention to improve bone mineral density 
in survivors of childhood acute lymphoblastic leukemia: BONEII, a prospective 
placebo-controlled double-blind randomized interventional longitudinal study 
design. Contemporary Clinical Trials, 29(5), 711–719. https://doi.org/10.1016/
j.cct.2008.05.002 
Reisi, N., Iravani, P., Raeissi, P., & Kelishadi, R. (2015). Vitamin D and bone minerals 
status in the long-term survivors of childhood acute lymphoblastic leukemia. 
International Journal of Preventive Medicine, 6(87). https://doi.org/10.4103/
2008-7802.164691 
Review Manager (RevMan) [Computer Program]. Version 5.3. Copenhagen: The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2014. 
62 
Revuelta Iniesta, R., Rush, R., Paciarotti, I., Rhatigan, E. B., Brougham, F. H. M., 
McKenzie, J. M., & Wilson, D. C. (2016). Systematic review and meta-analysis: 
Prevalence and possible causes of vitamin D deficiency and insufficiency in 
pediatric cancer patients. Clinical Nutrition, 35(1), 95–108. https://doi.org/
10.1016/j.clnu.2014.12.023 
Savitz, D. A., & Chen, J. H. (1990). Parental occupation and childhood cancer: review of 
epidemiologic studies. Environmental Health Perspectives, 88(16), 325–337. 
Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=
1568023&tool=pmcentrez&rendertype=abstract 
Schnabel, C., Jett, K., Friedman, J. M., Frieling, I., Kruse, H. P., & Mautner, V. (2013). 
Effect of vitamin D3 treatment on bone density in neurofibromatosis 1 patients: A 
retrospective clinical study. Joint Bone Spine, 80(3), 315–319. https://doi.org/
10.1016/j.jbspin.2012.07.010 
Schneider, P., Biko, J., Reiners, C., Demidchik, Y. E., Drozd, V. M., Capozza, R. F., … 
Ferretti, J. L. (2004). Impact of parathyroid status and Ca and vitamin-D 
supplementation on bone mass and muscle-bone relationships in 208 Belarussian 
children after thyroidectomy because of thyroid carcinoma. Experimental and 
Clinical Endocrinology and Diabetes, 112(8), 444–450. https://doi.org/10.1055/s-
2004-821204 
Schulte, C. M. S., & Beelen, D. W. (2004). Bone loss following hematopoietic stem cell 
transplantation : A long-term follow-up. Blood Journal, 103. https://doi.org/
10.1182/blood-2003-09-3081 
Schwarzer, G. (2007). Package “meta.” R News. https://doi.org/10.1007/978-3-319-
21416-0> 
Siegel, R., Miller, K. D., & Ahmedin, J. (2017). Cancer statistics. Ca: A Cancer Journal 
for Clinicians, 67(1), 7–30. https://doi.org/10.3322/caac.21387. 
Simmons, J. H., Chow, E. J., Koehler, E., Esbenshade, A., Smith, L.-A., Sanders, J., & 
Friedman, D. (2011). Significant 25-hydroxyvitamin D deficiency in child and 
adolescent survivors of acute lymphoblastic leukemia: treatment with 
chemotherapy compared with allogeneic stem cell transplant. Pediatric Blood & 
Cancer, 56(7), 1114–1119. https://doi.org/10.1002/pbc.22949 
Sinha, A., Avery, P., Turner, S., Bailey, S., & Cheetham, T. (2011). Vitamin D status in 
paediatric patients with cancer. Pediatric Blood Cancer, 57, 594–598. 
Swiatkiewicz, V., Wysocki, M., Odrowas-Sypniewska, G., Koltan, A., Manysiak, S., & 
Dylewska, K. (2003). Bone mass and bone mineral metabolism at diagnosis and 
after intensive treatment in children with acute lymphoblastic leukemia. Medical 
and Pediatric Oncology, 41(6), 578–580. https://doi.org/10.1002/mpo.10415 
63 
Tyler, L. S., Cole, S. W., May, J. R., Miliares, M., Valentino, M. A., Vermeulen, L. C., 
… Hawkins, B. (2008). ASHP Guidelines on the Pharmacy and Therapeutics 
Committee and the Formulary System. American Journal of Health-System 
Pharmacy, 65(13), 1272–1283. https://doi.org/10.2146/ajhp080086 
van der Sluis, I. M., van den Heuvel-Eibrink, M. M., Hählen, K., Krenning, E. P., & de 
Muinck Keizer-Schrama, S. M. (2000). Bone mineral density, body composition, 
and height in long-term survivors of acute lymphoblastic leukemia in childhood. 
Medical and Pediatric Oncology, 35(4), 415–420. https://doi.org/10.1002/1096-
911X(20001001)35:4<415::AID-MPO4>3.0.CO;2-9 
Viechtbauer, W. (2017). Package “metafor.” R package version 2.0-0, (1), 1–262. 
Retrieved from http://www.metafor-project.org/doku.php 
Wacker, M., & Holiack, M. F. (2013). Vitamin D-effects on skeletal and extraskeletal 
health and the need for supplementation. Nutrients, 5(1), 111–148. https://doi.org/
10.3390/nu5010111 
Wasilewski-Masker, K., Kaste, S. C., Hudson, M. M., Esiashvili, N., Mattano, L. A., & 
Meacham, L. R. (2008). Bone mineral density deficits in survivors of childhood 
cancer: long-term follow-up guidelines and review of the literature. Pediatrics, 
121(3), e705–e713. https://doi.org/10.1542/peds.2007-1396 
Watsky, M. A., Carbone, L. D., An, Q., Cheng, C., Lovorn, E. A., Hudson, M. M., … 
Kaste, S. C. (2014). Bone turnover in long-term survivors of childhood acute 
lymphoblastic leukemia. Pediatric Blood Cancer, 61(March 2014), 1451–1456. 
Wells, G., Shea, B., O’Connell, D., Peterson, J., Welch, V., Losos, M., & Tugwell, P. 
(2008). The Newcastle-Ottawa Scale (NOS) for assessing the quality of 
nonrandomised studies in meta-analyses. Ottawa, Ontario Canada. Retrieved 
from http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm (accessed 1 
January 2008). 
Wilson, L. C. (2016). The Prevalence of Military Sexual Trauma. Trauma, Violence, & 
Abuse, 152483801668345. https://doi.org/10.1177/1524838016683459 
Zeeb, H., & Greinert, R. (2010). The role of vitamin D in cancer prevention. Deutsches 
Aerzteblatt Online, 107(37), 638–643. https://doi.org/10.3238/arztebl.2010.0638 




THIS PAGE INTENTIONALLY LEFT BLANK  
65 
INITIAL DISTRIBUTION LIST 
1. Defense Technical Information Center 
 Ft. Belvoir, Virginia 
 
2. Dudley Knox Library 
 Naval Postgraduate School 
 Monterey, California 
